Current status of antitumor therapy with monoclonal antibodies.
The potential power of monoclonal antibodies arises from their ability to recognize single antigenic determinants in a complex mixture of molecules or cells. The possibilities for cancer therapy are apparent. But to what extent has the potential been realized? What problems have arisen in clinical trials?